These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
295 related articles for article (PubMed ID: 11818641)
21. Outcome in elderly patients undergoing primary coronary intervention for acute myocardial infarction: results from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. Guagliumi G; Stone GW; Cox DA; Stuckey T; Tcheng JE; Turco M; Musumeci G; Griffin JJ; Lansky AJ; Mehran R; Grines CL; Garcia E Circulation; 2004 Sep; 110(12):1598-604. PubMed ID: 15353506 [TBL] [Abstract][Full Text] [Related]
22. Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: the MULTISTRATEGY randomized trial. Valgimigli M; Campo G; Percoco G; Bolognese L; Vassanelli C; Colangelo S; de Cesare N; Rodriguez AE; Ferrario M; Moreno R; Piva T; Sheiban I; Pasquetto G; Prati F; Nazzaro MS; Parrinello G; Ferrari R; JAMA; 2008 Apr; 299(15):1788-99. PubMed ID: 18375998 [TBL] [Abstract][Full Text] [Related]
23. Abciximab therapy and unplanned coronary stent deployment: favorable effects on stent use, clinical outcomes, and bleeding complications. EPILOG Trial Investigators. Kereiakes DJ; Lincoff AM; Miller DP; Tcheng JE; Cabot CF; Anderson KM; Weisman HF; Califf RM; Topol EJ Circulation; 1998 Mar; 97(9):857-64. PubMed ID: 9521334 [TBL] [Abstract][Full Text] [Related]
24. Long-term clinical benefits of a platelet glycoprotein IIb/IIIa receptor blocker, abciximab (ReoPro), in high-risk diabetic patients undergoing percutaneous coronary intervention. Sim DS; Jeong MH; Kim W; Rhew JY; Yum JH; Kim JH; Cho JG; Ahn YK; Park JC; Ahn BH; Kim SH; Kang JC Korean J Intern Med; 2003 Sep; 18(3):129-37. PubMed ID: 14619381 [TBL] [Abstract][Full Text] [Related]
25. Predictors of and outcomes of early thrombosis following balloon angioplasty versus primary stenting in acute myocardial infarction and usefulness of abciximab (the CADILLAC trial). Dangas G; Aymong ED; Mehran R; Tcheng JE; Grines CL; Cox DA; Garcia E; Griffin JJ; Guagliumi G; Stuckey T; Lansky AJ; Stone GW; Am J Cardiol; 2004 Oct; 94(8):983-8. PubMed ID: 15476608 [TBL] [Abstract][Full Text] [Related]
26. Assessment of coronary angiograms prior to and after treatment with abciximab, and the outcome of angioplasty in refractory unstable angina patients. Angiographic results from the CAPTURE trial. van den Brand M; Laarman GJ; Steg PG; De Scheerder I; Heyndrickx G; Beatt K; Kootstra J; Simoons ML Eur Heart J; 1999 Nov; 20(21):1572-8. PubMed ID: 10529325 [TBL] [Abstract][Full Text] [Related]
27. A randomized trial comparing phosphorylcholine-coated stenting with balloon angioplasty as well as abciximab with placebo for restenosis reduction in small coronary arteries. Hausleiter J; Kastrati A; Mehilli J; Schühlen H; Pache J; Dotzer F; Glatthor C; Siebert S; Dirschinger J; Schömig A; J Intern Med; 2004 Nov; 256(5):388-97. PubMed ID: 15485474 [TBL] [Abstract][Full Text] [Related]
28. Effect of glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary-artery stents in acute myocardial infarction. Neumann FJ; Blasini R; Schmitt C; Alt E; Dirschinger J; Gawaz M; Kastrati A; Schömig A Circulation; 1998 Dec; 98(24):2695-701. PubMed ID: 9851955 [TBL] [Abstract][Full Text] [Related]
29. The long-term clinical results of a platelet glycoprotein IIb/IIIa receptor blocker (Abciximab: Reopro) coated stent in patients with coronary artery disease. Kim W; Jeong MH; Hong YJ; Lee SH; Park WS; Kim JH; Kim IS; Choi MJ; Ahn YK; Cho JG; Park JC; Cho DL; Kim H; Kang JC Korean J Intern Med; 2004 Dec; 19(4):220-9. PubMed ID: 15683110 [TBL] [Abstract][Full Text] [Related]
30. Abciximab in primary coronary stenting of ST-elevation myocardial infarction: a European meta-analysis on individual patients' data with long-term follow-up. Montalescot G; Antoniucci D; Kastrati A; Neumann FJ; Borentain M; Migliorini A; Boutron C; Collet JP; Vicaut E Eur Heart J; 2007 Feb; 28(4):443-9. PubMed ID: 17251257 [TBL] [Abstract][Full Text] [Related]
31. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. Stone GW; Grines CL; Cox DA; Garcia E; Tcheng JE; Griffin JJ; Guagliumi G; Stuckey T; Turco M; Carroll JD; Rutherford BD; Lansky AJ; N Engl J Med; 2002 Mar; 346(13):957-66. PubMed ID: 11919304 [TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of abciximab in combination with cilostazol in patients undergoing stenting. Hong EH; Kim MY; Park JE; Lee MH; Oh JM; Shin WG Int J Clin Pharmacol Ther; 2007 Jun; 45(6):355-65. PubMed ID: 17595893 [TBL] [Abstract][Full Text] [Related]
33. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. Topol EJ; Moliterno DJ; Herrmann HC; Powers ER; Grines CL; Cohen DJ; Cohen EA; Bertrand M; Neumann FJ; Stone GW; DiBattiste PM; Demopoulos L; N Engl J Med; 2001 Jun; 344(25):1888-94. PubMed ID: 11419425 [TBL] [Abstract][Full Text] [Related]
34. Comparison of coronary flow reserve and fractional flow reserve in patients with versus without diabetes mellitus and having elective percutaneous coronary intervention and abciximab therapy (from the PREDICT Trial). Kini AS; Kim MC; Moreno PR; Krishnan P; Ivan OC; Sharma SK Am J Cardiol; 2008 Mar; 101(6):796-800. PubMed ID: 18328843 [TBL] [Abstract][Full Text] [Related]
35. Effect of abciximab on angiographic complications during percutaneous coronary stenting in the Evaluation of Platelet IIb/IIIa Inhibition in Stenting Trial (EPISTENT). Islam MA; Blankenship JC; Balog C; Iliadis EA; Lincoff AM; Tcheng JE; Califf RM; Topol EJ; Am J Cardiol; 2002 Nov; 90(9):916-21. PubMed ID: 12398954 [TBL] [Abstract][Full Text] [Related]
36. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. Kastrati A; Mehilli J; Neumann FJ; Dotzer F; ten Berg J; Bollwein H; Graf I; Ibrahim M; Pache J; Seyfarth M; Schühlen H; Dirschinger J; Berger PB; Schömig A; JAMA; 2006 Apr; 295(13):1531-8. PubMed ID: 16533938 [TBL] [Abstract][Full Text] [Related]